Development stage biopharmaceutical company focusing on merging traditional therapies with psychedelic research Silo Pharma Inc. (OTCMKTS: SILO) has signed an agreement deal with Frontage Laboratories for Pharmacokinetic Study.
Frontage Laboratories is a contact research organization (CRO) which provides integrated, science-driven, product development services via the drug discovery and development process to enable life sciences companies to achieve their drug development goals.
The Pharmacokinetic Study in animals will be dose analyzed together with a full analysis of plasma samples. The CRO has worked with innovators and consumer health companies of different sizes to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets enabling successful development of various therapies important to patients.
“This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic. These solutions have the potential to enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They may be used to treat both Central Nervous System and Autoimmune Diseases,” said the CEO of Silo Pharma, Eric Weisblum.
